Courage Therapeutics is a leading neuroendocrine company co-founded by Dr. Roger Cone, a pioneering researcher in melanocortin receptor biology and the central melanocortin system's neural circuits in the brain. The company is dedicated to translating Dr. Cone's decades of work and discoveries of novel biological mechanisms of energy homeostasis into novel therapeutic candidates targeting the MC4R and MC3R receptors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/03/25 | $11,000,000 | Seed |
Arsenal Bridge Ventures | undisclosed |
